Protalix BioTherapeutics, Inc. (PLX)

Market Cap	129.60M
Revenue (ttm)	45.67M
Net Income (ttm)	-9.61M
Shares Out	73.63M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	3.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	344,121
Open	1.690
Previous Close	1.740
Day's Range	1.690 - 1.785
52-Week Range	0.820 - 1.900
Beta	0.74
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recomb...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 208
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PLX
• Website: https://www.protalix.com